BidaskClub cut shares of Tocagen (NASDAQ:TOCA) from a buy rating to a hold rating in a report published on Wednesday.

Separately, Zacks Investment Research cut shares of Tocagen from a hold rating to a sell rating in a research note on Tuesday, November 14th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. The company has a consensus rating of Hold and a consensus target price of $23.67.

Tocagen (TOCA) opened at $12.48 on Wednesday. Tocagen has a fifty-two week low of $8.60 and a fifty-two week high of $17.95. The company has a debt-to-equity ratio of 0.07, a current ratio of 6.03 and a quick ratio of 6.03. The firm has a market cap of $247.22 and a P/E ratio of -6.24.

Tocagen (NASDAQ:TOCA) last issued its quarterly earnings results on Wednesday, November 8th. The company reported ($0.50) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.02). The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.01 million. analysts expect that Tocagen will post -2.66 earnings per share for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Dowling & Yahnke LLC acquired a new stake in shares of Tocagen during the 4th quarter worth approximately $169,000. Blankinship & Foster LLC acquired a new stake in shares of Tocagen during the 4th quarter worth approximately $412,000. Schwab Charles Investment Management Inc. grew its stake in shares of Tocagen by 118.2% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 29,900 shares of the company’s stock worth $307,000 after purchasing an additional 16,200 shares during the period. Pure Financial Advisors Inc. acquired a new stake in shares of Tocagen during the 4th quarter worth approximately $1,324,000. Finally, Granahan Investment Management Inc. MA acquired a new stake in shares of Tocagen during the 3rd quarter worth approximately $392,000. 36.96% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Tocagen (TOCA) Downgraded to “Hold” at BidaskClub” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.watchlistnews.com/tocagen-toca-downgraded-to-hold-at-bidaskclub/1841587.html.

About Tocagen

Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.